SubHero Banner
Text

Rebinyn® (coagulation factor IX [recombinant] glycoPEGylated) – New drug approval

May 31, 2017 – Novo Nordisk announced the FDA approval of Rebinyn (coagulation factor IX [recombinant] glycoPEGylated) for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding.

Download PDF